% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • larshansson18 larshansson18 Jun 16, 2011 11:52 AM Flag

    Good finance and a more evident business plan

    the reimbusement was done a month ago in Sweden, now launch will come. As will there be in most of the EU countries before year end.

    1000 whole treatments is gross sales 50 MUSD, first milstone to Epicept except royalty.

    Will the agreement on Amiket be ready before holidays? Notice under the webcast that management seems to have choosen the partner for the CIPN-diagnosis. Billion USD market. Amiket will be the only approved drug in the diagnosis neuropathic pain in cancer.

    What is a reasonable deal, having the partner paying for the whole phase III? My sugestion is 20-30 million USD in upfront, 100 later on and an escalating double digit royalty. Approved 2014/2015?

    Though the risk is low, let's hope there is an emphasis on the royalty here. Ceplene will carry us to the approval for Amiket.

0.2278-0.0087(-3.68%)1:04 PMEDT